University of Patras
Τικαγκρελόρη έναντι κλοπιδογρέλης και επαναφόρτισης με τικαγκρελόρη σε ασθενείς με έμφραγμα του μυοκαρδίου με ανάσπαση του ST διαστήματος: μία φαρμακοδυναμική μελέτη
Abstract
dc:descriptionBACKGROUND In patients undergoing primary percutaneous coronary intervention (PPCI) in the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced death from vascular causes, myocardial infarction, or stroke in consistence with the overall trial results. Among patients allocated to the ticagrelor in the primary PCI cohort, 40.7% had received pre- randomization 600mg of clopidogrel. This scenario is frequently employed in real-world practice, as many patients receive initially clopidogrel loading dose (LD) followed by ticagrelor re-LD.OBJECTIVES To assess 2 strategies of P2Y12 inhibitor administration with the primary endpoint being that ticagrelor LD only is non-inferior to clopidogrel LD followed by ticagrelor re-LD, in terms of antiplatelet efficacy at 24 hours post randomization. METHODS In a prospective, 3-center, single-blind, investigator-initiated, parallel design study 74 P2Y12-naive patients undergoing primary PCI were randomized (Hour 0) to ticagrelor 180 mg LD vs clopidogrel 600 mg LD followed at 2 hours by ticagrelor re-LD. Platelet reactivity (VerifyNow, in PRU) was measured at Hour 0, 2, 4, 6 and 24 hours. The primary comparison was non-inferiority of ticagrelor to clopidogrel followed by ticagrelor re-LD regarding platelet reactivity at 24 h using a prespecified margin of <35 PRU for the upper bound of the one-sided 97.5% confidence interval (CI). ECG and enzyme release data were also analyzed.RESULTS Ticagrelor was proven non-inferior to clopidogrel followed by ticagrelor re-LD with a difference between arms of 13.5 PRU (28.8 upper 97.5% CI), p = 0.001. At Hour 2, platelet reactivity was lower in ticagrelor only vs clopidogrel followed by ticagrelor re- LD groups with least square estimate mean difference (95% CI) −105.7 (−140.6 to −70.8), p < 0.001, without significant difference thereafter. No differences in ECG analyzed parameters, cardiac enzyme release or adverse events up to 30 days were seen between groups.CONCLUSIONS In patients undergoing primary PCI, a strategy of ticagrelor LD only was proven non-inferior to clopidogrel LD followed by ticagrelor re-LD, in terms of antiplatelet efficacy at 24 hours post randomization and provided an earlier onset of platelet inhibition.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kontoprias, Kosmas
- Κοντοπρίας, Κοσμάς
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY_4_0
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49276